🇺🇸 FDA
Patent

US 12138263

Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors and methods of use thereof

granted A61KA61K31/4985A61K38/465

Quick answer

US patent 12138263 (Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors and methods of use thereof) held by Relay Therapeutics, Inc. expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Relay Therapeutics, Inc.
Grant date
Tue Nov 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K31/4985, A61K38/465, A61K45/06, A61K47/64